Celecoxib as Adjuvant Biologic Therapy in Patients With Head and Neck and Lung Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00527982|
Recruitment Status : Terminated (Termination due to poor accrual.)
First Posted : September 11, 2007
Results First Posted : April 20, 2011
Last Update Posted : December 6, 2012
- To examine the effect of celecoxib treatment on histological response, markers of proliferation (Ki-67), and apoptosis. Secondary endpoints include time to second primary or recurrence and survival.
- To examine the toxicity associated with celecoxib administration in patients with previously treated Head and Neck Head and neck squamous cell carcinomas (HNSCC)or Non-small-cell lung carcinoma (NSCLC).
|Condition or disease||Intervention/treatment||Phase|
|Head and Neck Cancer Lung Cancer||Drug: Celecoxib||Phase 2|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Celecoxib as Adjuvant Biologic Therapy in Patients With Early Stage Head and Neck and Lung Cancer|
|Study Start Date :||September 2005|
|Actual Primary Completion Date :||September 2008|
|Actual Study Completion Date :||September 2008|
Experimental: Celecoxib treatment
600 mg orally (PO) daily
600 mg by mouth daily for a total of 12 months.
Other Name: Celebrex
|No Intervention: No treatment|
- Histological Responses [ Time Frame: Baseline to 12 months ]Number of patients with histological response based on changes in bronchoscopies from baseline to 12 months.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00527982
|United States, Texas|
|U.T.M.D. Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Waun K. Hong, MD||M.D. Anderson Cancer Center|